Introduction
Stem cell factor (SCF), also termed Kit ligand, steel factor, or mast cell growth factor (Huang et al., 1990; Martin et al., 1990; Zsebo et al., 1990) , acts as an important growth factor for human mast cells (Galli et al., 1995) . In vitro it induces the proliferation and dierentiation of immature mast cells from bone marrow CD34+ progenitor cells (Rottem et al., 1994) . SCF also aids mast cell survival by inhibiting their apoptosis (Iemura et al., 1994) . Moreover, it is a potent chemotactic factor for mast cells (Nilsson et al., 1994) and promotes their adhesion to the extracellular matrix (Dastych & Metcalfe, 1994) . In addition, in vivo, SCF induces mast cell hyperplasia after subcutaneous injection in humans (Costa et al., 1996) . Finally, in vitro it greatly enhances antigeninduced degranulation of human lung-derived mast cells (Bischo & Dahinden, 1992) as well as inducing mast cell degranulation itself alone in vitro (Takaishi et al., 1994) and in vivo (Costa et al., 1996) . Therefore, SCF may be involved in many diseases associated with a local increase in the number and activation of mast cells, such as occurs in asthma (Ammit et al., 1997) .
In asthmatic patients, large quantities of the pro-in¯am-matory cytokine interleukin (IL)-1b have been reported in bronchoalveolar lavage (Borish et al., 1992) . IL-1b may be released by structural cells, such as epithelial cells (Devalia et al., 1993) and ®broblasts (Pan et al., 1996) , as well as by in®ltrated in¯ammatory cells, including eosinophils (Barnes, 1990 ) and mast cells (Moller et al., 1998) . IL-1b is known to upregulate the expression of many genes involved in the in¯ammatory process, including RANTES (Saji et al., 2000) , eotaxin (Ghaar et al., 1999) , IL-6 and IL-8 (Agarwal et al., 1995) and the IL-1b gene itself (Hiscott et al., 1993) . However, the eect of IL-1b on SCF expression by pulmonary cells is not known.
Glucocorticoids remain the major treatment for asthma. This treatment is associated with a reduced number of in®ltrated mast cells in the bronchial mucosa of asthmatic patients (Jeery et al., 1992) . Glucocorticoids aect cells in many ways, but their major therapeutic bene®t is likely to occur through the regulation of the expression of genes involved in in¯ammation (for review, see Barnes & Adcock, 1993) . In particular, as recently reported by Kassel et al. (1998) , the regulation of the constitutive expression of SCF by glucocorticoids shows a time-dependent biphasic eect in human lung ®broblasts in culture.
Here we report our investigation of the regulation of SCF expression in in¯ammatory conditions mimicked by the addition of IL-1b, and the eect of the glucocorticoids budesonide and dexamethasone on the IL-1b-induced SCF expression by human pulmonary ®broblasts in culture.
Methods

Culture of human lung fibroblasts
Human lung derived ®broblasts were obtained by the explant technique, as previously described (Kassel et al., 1998) . Brie¯y, macroscopically normal human lung tissue was separated into fragments within 1 h of resection for bronchocarcinoma. Fibroblasts were cultured in Dulbecco's modi®ed Eagle's medium (DMEM)/F-12 (1 : 1) (GIBCO BRL, Cergy Pontoise, France), supplemented with 10% foetal calf serum (FCS), penicillin and streptomycin, and incubated in a humidi®ed mixture of 95% air and 5% CO 2 at 378C. They were then replated in 25 cm 2 tissue culture¯asks (Costar, Acton, MA, U.S.A.) and were characterized as ®broblasts morphologically and by immunocytochemistry with an anti®broblast monoclonal antibody (5B5) (DAKO S.A., Trappes, France). They subsequently were split 1 : 4 at con¯uence and passaged. Fibroblasts were used at passage 7.
Cell treatment
At con¯uence, ®broblasts were placed into a quiescent state by reducing the FCS content to 0.3% (starving medium) for 48 h. IL-1b (ROCHE Diagnostics, Meylan, France), prepared from a 2 mg ml 71 stock solution, was added at a ®nal concentration of 400 pg ml
71
. The glucocorticoid budesonide (kindly provided by Dr R. Brattsand, Astra, Lund, Sweden) was prepared from a 10 mM stock solution in absolute ethanol and used at 0.1 mM. Dexamethasone (Sigma Chemicals, St Louis, MO, U.S.A.) was used at 1 mM in similar conditions. The glucocorticoid antagonist RU486 (Sigma Chemicals) was prepared from a 10 mM stock solution in absolute ethanol and incubated at 1 mM for 1 h before IL-1b and glucocorticoid treatments. Similar experiments were performed with staggered treatment starts, to verify the eect of the duration of the culture. Supernatants were sampled and stored at 7808C until the SCF protein assay. Fibroblasts were harvested for total RNA extraction.
For analysis of the transcript stability, con¯uent ®broblasts were treated with solvent alone (ethanol; 1 mM), IL-1b (400 pg ml 71 ), budesonide (0.1 mM) or the combination of both for 2.5 or 10 h. Supernatants were replaced by the starving medium, which contained 5 mg ml 71 actinomycin D (Sigma Chemicals). Cells were harvested at every hour from 0 to 4 h and total RNA was extracted.
SCF ELISA
Immunoreactive SCF released in the supernatant of ®bro-blasts treated with cytokine, glucocorticoid, and/or RU486, and the control ®broblasts treated only with solvent was quanti®ed by a sensitive ELISA procedure. It used a capture anti-human SCF monoclonal antibody (clone 13302.6; R&D Systems Europe, Abingdon, U.K.) and a biotinylated detection anti-human SCF polyclonal antibody (R&D Systems Europe), revealed by extravidin-horseradish peroxidase (Sigma) and a 3,3',5,5'-tetramethylbenzidine liquid substrate system (Sigma Chemicals). Standard curves were generated with recombinant human SCF (R&D Systems Europe) diluted in the starving medium and were linear from 3.9 to 500 pg ml
71
.
Extraction of total RNA and reverse transcription
Total RNA was extracted from control or treated ®broblasts with TriReagent 1 (Molecular Research Center Inc., Cincinnati, OH, U.S.A.). Isolated RNA was diluted in RNase-free water and quanti®ed by absorbance measurement at 260 nm. Four mg of total RNA were incubated with 0.5 mg of random primers for 5 min at 708C and allowed to cool down to room temperature. RNA was subsequently reverse transcribed in 16 reverse transcription (RT) buer (75 mM KCl, 3 mM MgCl 2 , 10 mM dithiothreitol, and 50 mM Tris-HCl, pH 8.3) that contained 1 unit ml 71 RNasin ribonuclease inhibitor, 1 mM of each dNTP, and 10 units ml 71 RNase H(7)-Moloney leukaemia virus reverse transcriptase (all reagents from Promega, Madison, WI, U.S.A.). The reaction was conducted for 1 h at 378C, and the reverse transcriptase was then heat-inactivated at 998C for 5 min.
Quantification of SCF cDNA
Quanti®cation of SCF cDNA was performed by polymerase chain reaction (PCR), and the results were normalized to total cDNA. PCR of SCF cDNA SCF cDNA was ampli®ed from total cDNA obtained after reverse transcription by online¯uor-escent PCR (LightCycler 2 -SYBR Green I, ROCHE Diagnostics), with primers that lead to a single 149 bp PCR product. PCR reactions were performed in 16 PCR reaction buer (2 ml of the reaction mix containing FastStart Taq DNA polymerase, dNTP mix, SYBR Green I, 3 mM MgCl 2 ) (all from ROCHE Diagnostics), and 10 pmol of each primer: sense primer: 5'-TGGATAAGCGAGATGGTAGT-3', antisense primer: 5'-TTTTCTTTCACGCACTCCAC-3', in a 20 ml ®nal volume for 35 cycles. Each cycle consisted of 15 s denaturation at 958C, 10 s annealing at 538C, and 10 s extension at 728C. Ampli®ed SCF cDNA was analysed on-line by¯uorescence, and quanti®ed during the exponential state.
The standard SCF cDNA was obtained from pulmonary ®broblast total cDNA. After ampli®cation by PCR with the primers described above, the 149 bp-PCR products were electrophoresed on a 2% agarose gel stained with ethidium bromide, puri®ed on QIAEX II (QIAEX II gel extraction kit, QIAGEN, Courtaboeuf, France), and quanti®ed by¯uores-cence (PicoGreen 1 , Molecular Probes Inc.) according to a standard curve obtained with double-stranded phage l DNA (0 ± 1 mg ml
71
). This puri®ed SCF cDNA was used as a standard curve from 1 to 300 fg ml
. Quanti®cation of total cDNA One ml of total cDNA was diluted (1 : 15) and added to 250 ml Tris-EDTA (TE) 16 buer (10 mM Tris-HCl, pH 7.8, 1 mM EDTA, pH 8). This reaction mix was incubated with 250 ml OliGreen 1 (1 : 200) (Molecular Probes Inc., Eugene, Oregon, U.S.A.) for 10 min in the dark. Simultaneously, a standard single-stranded M13 phage DNA (Sigma) curve (0 ± 500 ng ml 71 ) was obtained in the same conditions. The total cDNA was quanti®ed in ā uorometer (Hitachi F-2000, Tokyo, Japan) at an excitation wavelength of 480 nm and an emission wavelength of 520 nm. Total cDNA remained unchanged over time and for all treatments.
Expression of results and statistical analysis
SCF cDNA was calculated as fg SCF cDNA/ng total cDNA, and SCF protein was calculated in pg ml
71
. The values after treatment were expressed as a percentage of the control values. Results are the means+s.e.mean of n=4 experiments performed in duplicate. Statistical analysis of the results used Student's t-test, or Student-Newman-Keuls when more than two variables were compared. Values of P50.05 were considered signi®cant.
Results
Effect of IL-1b on SCF production SCF mRNA IL-1b (400 pg ml 71 ) signi®cantly increased SCF mRNA expression by human lung ®broblasts in culture (Figure 1a, b) . This increase reached +91% at 2.5 h (128.2+51.4 fg ng 71 total cDNA for control and 245.9+99.4 for IL-1b-treated ®broblasts; P50.001, n=4) (Figure 1a ). This eect decreased over time, but was still signi®cant at 10 h (+39%; 75.3+23.7 fg ng 71 total cDNA for control and 102.6+36.6 for IL-1b-treated ®broblasts; P50.01, n=4) (Figure 1b) . SCF protein SCF protein production also increased after treatment with IL-1b (Figure 1c,d) . At 2.5 h, this increase reached +32% (36.8+1.6 pg ml 71 for control and 48.7+3.3 for IL-1b-treated ®broblasts; P50.01, n=4) (Figure 1c) . At 10 h, the increase was less but still signi®cant (+16%; 74.3+12.1 pg ml 71 for control and 85.7+14.6 for IL-1b-treated ®broblasts; P50.05, n=4) (Figure 1d ). Similar results were obtained when IL-1b treatment was staggered to stop the cell culture at the same time. This ®nding con®rmed that the IL-1b eect we observed was not due to a modi®cation in the cell phenotype over time.
Effect of budesonide on IL-1b-induced SCF production SCF mRNA Budesonide (0.1 mM) inhibited the IL-1b-induced increase in SCF mRNA expression (Figure 1a,b) . This inhibition reached 68% at 2.5 h (165.7+64.1 fg ng 71 total cDNA; P50.01, n=4) (Figure 1a ) and continued so that this expression was below the baseline at 10 h (192% inhibition; 42.4+4.4 fg ng 71 total cDNA; P50.01, n=4) (Figure 1b) . Conversely, as previously shown (Kassel et al., 1998) , budesonide alone caused SCF mRNA expression to decrease below baseline at 2.5 h (736%; 85.7+35.7 fg ng 71 total cDNA; P50.001, n=4) (Figure 1a) , whereas it provoked a slight increase at 10 h (+17% compared with baseline expression; 91.5+30.1 fg ng 71 total cDNA; P50.05, n=4) (Figure 1b) . SCF protein The modulation by budesonide over time was dierent for the IL-1b-induced increase of SCF protein than for that of SCF mRNA (Figure 1c,d) . A surprising increase over IL-1b-induced expression alone was observed at 2.5 h (61%; 56.0+1.0 pg ml 71 SCF; P50.001, n=4) ( Figure 1c ). As was expected from the mRNA modulation, however, total inhibition of the eect of IL-1b was observed at 10 h (79% as compared with baseline expression; 64.6+9.3 pg ml 71 SCF; P50.05, n=4) (Figure 1d ). Conversely, budesonide alone caused SCF protein expression to decrease at 2.5 h (713%; 32.1+1.7 pg ml 71 SCF; P50.01, n=4) ( Figure 1c ) and at 10 h (711%; 66.0+13.4 pg ml 71 SCF; P50.05, n=4) (Figure 1d ).
Results were similar with dexamethasone (Table 1) : the eect of the glucocorticoids was totally opposite in constitutive and in¯ammatory conditions.
Effect of RU486 on SCF expression
To verify that these eects depended on the glucocorticoid receptor, we evaluated the eect of the glucocorticoid-receptor antagonist RU486 on the budesonide-induced eects.
SCF mRNA (Figure 1a ,b) RU486 (1 mM) by itself had no eect on SCF mRNA constitutive expression (130.3+53.0 fg ng 71 total cDNA; n=4 at 2.5 h; 79.0+23.1 fg ng 71 total cDNA, n=4 at 10 h). In addition, RU486 antagonized both eects of budesonide: the decrease in SCF mRNA expression at 2.5 h (138.2+56.7 fg ng 71 total cDNA for RU486+budesonide-treated ®broblasts; P50.05, n=4) (Figure 1a) , and the increase induced by budesonide alone at 10 h (75.1+21.1 fg ng 71 total cDNA; n=4) (Figure 1b) , as well as the inhibiting eect of budesonide on the IL-1b-stimulated SCF mRNA expression at 2.5 h (197.7+3.8 fg ng 71 total cDNA; NS, n=4) ( Figure 1a) and at 10 h (91.3+22.1 fg ng 71 total cDNA; NS, n=4) (Figure 1b ). However, RU486 alone slightly decreased the IL-1b-stimulated SCF mRNA expression at 2.5 h by 28% (212.6+83.6 fg ng 71 total cDNA for RU486+IL-1b-treated ®broblasts; P50.001, n=4) (Figure 1a) , but not at 10 h (92.6+23.0 fg ng 71 total cDNA; NS, n=4) (Figure 1b) . (Figure 1c,d ) RU486 had no eect on SCF constitutive protein expression (35.0+2.2 pg ml 71 SCF; n=4 at 2.5 h; 74.6+12.1 pg ml 71 SCF; n=4 at 10 h). Similarly, it totally cancelled out the eect of budesonide alone at 2.5 h (37.4+1.5 pg ml 71 SCF; n=4) ( Figure 1c ) and at 10 h (75.7+11.0 pg ml 71 SCF; n=4) (Figure 1d ). It also cancelled out the eect of budesonide on the IL-1b-enhanced SCF protein expression at 2.5 h (48.0+0.3 pg ml 71 SCF; NS, n=4) (Figure 1c ) and the inhibition induced at 10 h (87.8+0.7 pg ml 71 SCF; NS, n=4) (Figure 1d ). Finally, RU486 had no eect on the IL-1b-enhanced SCF protein expression at 2.5 h (48.0+3.0 pg ml 71 SCF; P50.001, n=4) (Figure 1c) or at 10 h (80.3+14.1 pg ml 71 SCF; P50.05, n=4) (Figure 1d ). Similar results were observed with dexamethasone (Table 1) .
SCF protein expression
SCF mRNA stability
The mechanism of the glucocorticoid-induced eects in IL1b-treated ®broblasts was analysed by evaluating the stability of the SCF mRNA by measuring its half-life (t 1/2 ) after adding actinomycin D.
At 2.5 h (Figure 2a) , the estimated half-life of SCF mRNA was 2.0 h in the control ®broblasts treated with solvent alone. IL-1b treatment signi®cantly increased SCF mRNA stability to t 1/2 =3.8 h (compared with control, P50.001). The addition of budesonide slightly decreased this enhanced stability, to t 1/2 =3.1 h, still signi®cantly higher than the control (P50.001). Budesonide alone, on the other hand, signi®cantly decreased the stability of the SCF mRNA to t 1/2 =1.2 h (compared with control, P50.001).
At 10 h (Figure 2b ), the estimated half-life was 3.4 h in the control cells, thereby showing that SCF mRNA stability increases with time. Treatment with either IL-1b or budesonide did not signi®cantly modify this stability British Journal of Pharmacology vol 135 (7) SCF expression and glucocorticoids in inflammation C.A. Da Silva et al(t 1/2 =3.5 h and 3.8 h, respectively, NS). The combination of IL-1b and budesonide markedly decreased it, however (t 1/2 =2.4 h, P50.001).
Discussion
We present here evidence that (1) the pro-in¯ammatory cytokine IL-1b substantially increases the expression of SCF mRNA and protein by human lung ®broblasts in culture, and (2) that this increased expression is markedly regulated by the glucocorticoids budesonide and dexamethasone.
This ®rst ®nding, that IL-1b, present in large amounts in the human airways of asthmatic patients (Borish et al., 1992) , heightens SCF mRNA expression, is in agreement with the reported increase in the IL-1b-mediated expression of genes implicated in the in¯ammatory process, such as cyclooxygenase (COX)-2 mRNA expression by human pulmonary epithelial cells (Lin et al., 2000) or eotaxin mRNA expression in A549 airway epithelial cells (Jedrzkiewicz et al., 2000) . Both reports propose a mechanism for this increased expression associated with the activation of the transcription factor nuclear factor (NF)-kB by IL-1b (Jedrzkiewicz et al., 2000; Lin et al., 2000) ; this mechanism would involve gene promoters with at least one NF-kB responsive element. One such element has been identi®ed in the SCF gene promoter (Taylor et al., 1996) , although its speci®c role in SCF gene expression is not yet known.
We also observed that when SCF expression increased, its mRNA became more stable (had a longer half-life). This is consistent with the increased stability of COX-2 mRNA observed in HeLa cells stimulated by IL-1b (Ridley et al., 1998) and of inducible nitric oxide synthase mRNA in cardiac myocytes (Oddis et al., 1995) . Among the mechanisms involved in increased mRNA stability is the length of the poly(A) + tail (Ross, 1995) , and it has been proposed that Il-1b increases the process of polyadenylation (Stoeckle, 1992) , which might play a part in this eect. Accordingly, SCF Eect of IL-1b (400 pg ml 71 ), dexamethasone (1 mM) and/or RU486 (1 mM) on SCF mRNA and protein expression by human lung ®broblasts in culture at 2.5 h and 10 h. SCF cDNA was quanti®ed by on-line¯uorescent PCR, and SCF protein by ELISA. Results were normalized to total cDNA, which did not vary over time. Results are expressed as (SCF cDNA)/(total cDNA) in fg ng
71
. SCF protein levels were assessed in the supernatant by ELISA and results are expressed as (SCF protein) in pg ml
. Results are mean values+s.e.mean of four experiments performed in duplicate on ®broblasts from three dierent donors. British Journal of Pharmacology vol 135 (7) SCF expression and glucocorticoids in inflammation C.A. Da Silva et almRNA and protein behave like many other proin¯ammatory factor genes: their expression increases in the presence of IL1b. These genes include COX-2 (Lin et al., 2000) , RANTES (Saji et al., 2000) , IL-6 and IL-8 (Agarwal et al., 1995) , eotaxin (Ghaar et al., 1999) and NGF (Olgart & Frossard, 2001 ).
Budesonide is the major anti-in¯ammatory compound used in the treatment of diseases such as asthma that are associated with an increased number of tissue mast cells. Here we studied its eect on SCF expression in in¯ammatory conditions created by IL-1b, rather than the previouslyreported eects on its constitutive expression (Kassel et al., 1998) . We showed here that budesonide inhibited the IL-1b-induced increase in SCF mRNA and protein expression in the short term (2.5 h) and even more so longer after treatment (10 h). This eect is consistent with many others reported in the literature, where glucocorticoids inhibit the expression of genes involved in the in¯ammatory process, including IL-4 and 5 (Bentley et al., 1996) or IL-1b (Sousa et al., 1997) (for review, see Barnes et al., 1998) . We have demonstrated here that this inhibitory eect involves the destabilization of SCF mRNA in the short term and its aggravation after a longer period.
The precise mechanisms of glucocorticoids action in SCF mRNA stability is unclear. It has been suggested that AU-rich elements in the 3'-untranslated region play some role in the glucocorticoid-induced decrease in mRNA stability (Peppel et al., 1991; Ristimaki et al., 1996) , but none have been found in the human SCF mRNA sequence (Martin et al., 1990) . Hence, the observed SCF mRNA destabilization probably involves another mechanism, as yet unidenti®ed. Possibilities include the down-regulation of Poly(A) + binding proteins (PABP) or dysregulation of the 5'-Catabolite gene Activator Protein (CAP) that protects mRNA from degradation (Ross, 1995) . Other currently unknown mechanisms may also play a role in the inhibition by budesonide of IL-1b-stimulated SCF expression. Since the SCF gene promoter has NF-kB and AP-1 responsive elements (Taylor et al., 1996) , a direct interaction between activated GR and these transcription factors may be involved. This interaction has been proposed as a general mechanism (Adcock, 2001) and been shown to exist in speci®c cases between GR and NF-kB, involving repression of histone acetyl transferase activity activated by p65 (Ito et al., 2001) and between GR and AP-1 (Diamond et al., 1990; Kerppola et al., 1993) . Nevertheless, we also noticed that the short-term increase in SCF protein expression induced by the combination of IL-1b and budesonide was substantially greater than that induced by IL-1b alone, conversely to the decreased SCF mRNA expression. This surprising eect may be related to an earlier increase in SCF mRNA expression, to a rapid increase of the translational process after short term treatment by glucocorticoids, or to both. However, SCF gene expression is not described in the literature as an early gene and thus not regulated in the same way as the early gene family. The mechanism of this interesting event requires further investigation.
Additionally, we have demonstrated here that all the results obtained with budesonide were glucocorticoid-receptor dependent, since RU486, a glucocorticoid-receptor antagonist (Cairns et al., 1993) , cancelled out all the eects induced by budesonide on SCF mRNA and protein expression, whether or not IL-1b was present. RU486 alone exerted a slight inhibitory eect on IL-1b-induced SCF mRNA expression. Since RU486 had no eect on control cells or on SCF mRNA stability (not shown), we may hypothesize that upon IL-1b stimulation, RU486 interacts with the transductional pathways activated by IL-1b. In accordance with this hypothesis, it has been reported that RU486, after binding to the glucocorticoid receptor (GR), interacts with the transcription factor NF-kB and inhibits NF-kB activity without aecting the latter's binding to DNA (Hofmann et al., 1998; Liden et al., 1997) , through interaction with a histone acetyltransferase/ NF-kB complex (Ito et al., 2001) . A similar mechanism may thus be proposed to explain the decrease in IL-1b-enhanced SCF mRNA expression shown in this study.
In conclusion, our study clearly shows that IL-1b, a proin¯ammatory cytokine present in large quantities in the airways of asthmatic patients, and here mimicking the in¯ammatory conditions in human lung ®broblasts in vitro, increases SCF expression, at least partly by increasing the stability of its mRNA. Moreover, anti-in¯ammatory glucocorticoids decreased this IL-1b-enhanced SCF expression and the stability of its mRNA. This may be of major importance in the mechanism of glucocorticoid treatment of diseases associated with an increased number of mast cells in tissues, such as asthma. Our results thus suggest a new mechanism of glucocorticoid action, through the regulation of the expression of the mast cell growth factor SCF.
